SCHEMBL4119850

SCHEMBL4119850

COc1cccc(C(=O)c2cccc(Cl)c2N)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
MAPK14 Q16539 3/20 0.50
GAA P10253 2/20 0.50
HSD17B10 Q99714 2/20 0.50
RAB9A P51151 6/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
NPC1 O15118 4/20 0.49
ALDH1A1 P00352 3/20 0.49
LMNA P02545 3/20 0.49
KDM4E B2RXH2 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
TP53 P04637 2/20 0.44
ATM Q13315 1/20 0.43
POLB P06746 1/20 0.43
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9566962 0.88 MAPK14 (0.62) KMT2AMAPK14GAAHSD17B10RAB9A
SCHEMBL3762150 0.84 RAB9A (0.55) KMT2AGAAHSD17B10RAB9ASMN1; SMN2
SCHEMBL4111431 0.83 RAB9A (0.47) KMT2AMAPK14GAAHSD17B10RAB9A
SCHEMBL635552 0.80 RECQL (0.56) KMT2AMAPK14GAAHSD17B10RAB9A
SCHEMBL8467508 0.79 RAB9A (0.52) KMT2AGAAHSD17B10RAB9ASMN1; SMN2
SCHEMBL10589919 0.78 KMT2A (0.50) KMT2AGAAHSD17B10RAB9ASMN1; SMN2
SCHEMBL6650992 0.76 GAA (0.49) KMT2AGAAHSD17B10RAB9ASMN1; SMN2
SCHEMBL4124280 0.75 ATM (0.51) KMT2AGAAHSD17B10RAB9ASMN1; SMN2
SCHEMBL4111182 0.75 MAPK14 (0.49) KMT2AMAPK14GAAHSD17B10RAB9A
SCHEMBL7947086 0.75 KMT2A (0.51) KMT2AGAARAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR KMT2A 1467/4885MAPK14 4368/4885GAA 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.